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Abstract
Background: The World Health Organization recommends all men who have sex with men (MSM) receive Hepatitis
B Virus (HBV) and Hepatitis C Virus (HCV) testing. MSM in China are a high-risk group for HBV and HCV infection, but
test uptake is low. Crowdsourcing invites a large group to solve a problem and then shares the solution with the
public. This nationwide online randomized controlled trial will evaluate the effectiveness of a crowdsourced
intervention to increase HBV and HCV testing among MSM in China.
Methods: Seven hundred MSM will be recruited through social media operated by MSM organizations in China.
Eligible participants will be born biologically male, age 16 years or older, report previous anal sex with another man,
and reside in China. After completing a baseline online survey, participants will be randomly assigned to intervention
or control arms with a 1:1 allocation ratio. The intervention will include two components: (1) a multimedia component
will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest
in China; (2) a participatory component will invite men to submit suggestions for how to improve crowdsourced
videos and images. The control arm will not view any images or videos and will not be invited to submit suggestions.
All participants will be offered reimbursement for HBV and HCV testing costs. The primary outcome is HBV and HCV
test uptake confirmed through electronic submission of test report photos within four weeks of enrolment. Secondary
outcomes include self-reported HBV and HCV test uptake, HBV vaccination uptake, and change in stigma toward
people living with HBV after four weeks. Primary and secondary outcomes will be calculated using intention to treat
and as-exposed analyses and compared using two-sided 95% confidence intervals.
Discussion: Few previous studies have evaluated interventions to increase HBV and HCV testing in middle-income
countries with a high burden of hepatitis. Delivering a crowdsourced intervention using social media is a novel
approach to increasing hepatitis testing rates. HBV and HCV test uptake will be confirmed through test report photos,
avoiding the limitations of self-reported testing outcomes.
Trial registration: NCT03482388 (29 March 2018).
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Background
Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are
substantial contributors to global morbidity and mortality,
together accounting for more deaths annually than HIV
[1]. Most individuals affected by chronic viral hepatitis are
in low- and middle-income countries (LMIC) [2]. China is
a middle-income country with a high burden of hepatitis
[3]. HBV and HCV prevalence among the general popula-
tion in China is 7% and 0.8%, respectively, and China
alone has more persons living with chronic viral hepatitis
than Europe and the Americas combined [2–4].
Men who have sex with men (MSM) are a group at
increased risk for HBV and HCV infection [5, 6]. Preva-
lence of HBV and HCV is higher among MSM than the
general population in multiple contexts, [7–10] includ-
ing China [11, 12]. As a result, the World Health
Organization (WHO) guidelines recommend all MSM
receive HBV and HCV testing at least once [13]. Testing
is the key first step in the viral hepatitis care continuum
and is necessary for infected persons to be linked to
care, initiated on treatment, and to achieve viral
suppression or cure. Expedited linkage to the viral
hepatitis care continuum can reduce liver-related
deaths, [14, 15] and hepatitis testing can identify
those susceptible to HBV infection and facilitate
vaccination [16].
Despite the importance of testing, HBV and HCV test-
ing rates among MSM in China are low. A 2017 nation-
wide online survey of MSM in China found 59% had
never HCV tested, and among those with no or uncer-
tain HBV vaccination, 62% had never HBV tested [17].
Chinese MSM who had not HBV or HCV tested were
also less likely to have received screening for HIV and
other sexually transmitted infections (STI) [17]. Novel
methods of increasing hepatitis testing and linkage to
HIV/STI testing services among MSM are needed.
HBV and HCV testing services can be potentially
strengthened using crowdsourcing. Crowdsourcing in-
vites a large group to solve a problem and then shares
the solution with the public [18]. This bottom-up
approach can spur innovation through collecting and
refining a wide-range of creative solutions from a diverse
group of contributors [13]. Additionally, crowdsourcing
engages communities in the development of responses
to important issues, thereby increasing community
participation and producing more locally relevant
solutions [19, 20].
Crowdsourcing has been used to identify health
innovation by many funders, including the United States
National Institutes of Health, the English National
Health Service, the Bill and Melinda Gates Foundation,
and the United States government [21, 22].
Non-inferiority randomized controlled trials (RCTs) have
shown that crowdsourcing is a cost-effective tool for
increasing HIV testing uptake and is as efficacious as
evidence-based health marketing materials [23, 24].
Additionally, social media interventions that involve
active participation and content generation, such as
crowdsourcing, have been associated with higher rates of
HIV and STI testing compared to passive testing
campaigns [25].
Few previous studies have evaluated interventions to
increase hepatitis testing in LMIC, and none of these
have targeted MSM or used a crowdsourcing approach
[26]. The purpose of this RCT is to address this gap in
the current literature and evaluate the impact of a
crowdsourced intervention on HBV and HCV test
uptake among MSM in China.
Objectives
Specific aim 1: To compare confirmed HBV and HCV
test uptake as a composite endpoint between MSM ran-
domly assigned to a crowdsourced intervention and
MSM randomly assigned to control.
Hypothesis 1: MSM assigned to the crowdsourced
intervention will have a higher rate of HBV and HCV
test uptake compared to MSM in the control arm.
Specific aim 2: To compare change in stigma toward
people living with HBV between MSM randomly
assigned to a crowdsourced intervention and MSM ran-
domly assigned to control.
Hypothesis 2: MSM assigned to the crowdsourced
intervention will have greater reduction in stigma to-
ward people living with HBV compared to MSM in the
control arm.
Specific aim 3: To compare self-reported linkage to
clinical visits about hepatitis, HBV vaccination, and
HIV/STI testing services between MSM randomly
assigned to a crowdsourced intervention and MSM ran-
domly assigned to control.
Hypothesis 3: MSM assigned to the crowdsourced
intervention will have improved linkage to clinical visits
about hepatitis, HBV vaccination, and HIV/STI testing
services compared to MSM in the control arm.
Methods
Trial design and timeline
This study will be an online superiority RCT. After com-
pleting a baseline survey to assess eligibility, enrolled
participants will be randomly assigned in a 1:1 ratio into
the intervention or control arms. Men randomly
assigned to the intervention arm will be asked to view
four crowdsourced images and videos promoting hepa-
titis testing over 8 days. After viewing each image or
video men will be invited to submit suggestions for how
to better tailor the crowdsourced materials to the MSM
community. Men randomly assigned to the control arm
will view no materials and will not be invited to submit
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suggestions. Participants can submit photos of hepatitis
test reports to confirm HBV and HCV test uptake at any
time after enrolment. After 3 weeks men will be sent a
message asking them to complete a follow-up survey
within 1 week. All participants will be assessed for pri-
mary and secondary outcomes at 4 weeks (28 days)
post-enrolment (Table 1). The study is anticipated to
begin enrolment in April 2018 and finish data collection
by June 2018. A flowchart summarizing trial design and
timeline is presented in Fig. 1.
Study setting and recruitment
This study will be conducted online. All recruitment, en-
rolment, intervention delivery, and data collection will
occur through mobile phones and social media smart-
phone apps. Nearly 70% of the adult population in China
owns a smartphone, and 95% of all netizens in China ac-
cess the internet using a mobile phone [27, 28]. In this
study, participants will be recruited through an an-
nouncement promoted via social media accounts oper-
ated by several local MSM organizations. The
announcement will include a link connecting men to the
online baseline survey to be completed using a smart-
phone. The link will remain active until 700 eligible men
have enrolled.
Once enrolled, WeChat (Tencent Holdings Limited,
Shenzhen, China) will be used to deliver messages and
collect confirmatory photos of hepatitis test reports from
participants. Additionally, men randomly assigned to the
intervention arm will view crowdsourced images and
videos through WeChat. WeChat is a multipurpose so-
cial media smartphone app with messaging and
Table 1 Primary and secondary outcomes with definitions
Primary outcome Definition
Confirmed HBV and HCV test uptake Defined as men who had both HBsAg test uptake and anti-HCV IgG test uptake confirmed
through electronic submission of a test report photo showing serology results, age of tester,
sex of tester, and date of test within four weeks of enrolment
Secondary outcomes
Confirmed HBV test uptake Defined as men who had HBsAg test uptake confirmed through electronic submission of a
test report photo showing serology results, age of tester, sex of tester, and date of test within
four weeks of enrolment
Confirmed HCV test uptake Defined as men who had anti-HCV IgG test uptake confirmed through electronic submission
of a test report photo showing serology results, age of tester, sex of tester, and date of test
within four weeks of enrolment
Self-reported HBV test uptake Defined as men who had HBsAg uptake within four weeks of enrolment, self-reported in
follow-up survey
Self-reported HCV test uptake Defined as men who had anti-HCV IgG uptake within four weeks of enrolment, self-reported in
follow-up survey
HBV vaccination uptake Defined as men who had receipt of at least a one dose of the HBV vaccine within four weeks
of enrolment, self-reported in follow-up survey
HBV vaccination uptake among men with confirmed
susceptibility to HBV infection
Defined as men with negative HBsAg and negative anti-HBs results confirmed through elec
tronic submission of a test report photo showing serology results, who had receipt of at least
one dose of the HBV vaccine within four weeks of enrolment, self-reported in follow-up
survey
HIV test uptake Defined as men who had HIV test uptake within four weeks of enrolment, self-reported in
follow-up survey
Chlamydia test uptake Defined as men who had chlamydia test uptake within four weeks of enrolment, self-reported
in follow-up survey
Gonorrhoea test uptake Defined as men who had gonorrhoea test uptake within four weeks of enrolment, self-
reported in follow-up survey
Syphilis test uptake Defined as men who had syphilis test uptake within four weeks of enrolment, self-reported in
follow-up survey
Change in stigma toward people living with HBV Continuous variable, defined as difference between Toronto Chinese HBV Stigma Scale score
assessed at follow-up and baseline. Stigma toward people living with HBV will be measured at
baseline and follow-up using 20 survey items that are each on a five point Likert scale. The 20
items were originally developed as the Toronto Chinese HBV Stigma Scale (potential range of
20–100), which has been previously validated and correlated to HBV testing behaviours among
Chinese populations [39]. Decreased stigma toward people living with HBV will be defined as
a mean composite score that is less at follow-up compared to baseline.
Visit with a physician after hepatitis test uptake Defined as men who had HBV and/or HCV test uptake and saw a physician to discuss hepatitis
test results within four weeks of enrolment, self-reported in follow-up survey
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multimedia functionality. The app had approximately 900
million daily active users in 2017, most of whom live in
China, and is commonly used to send and share private
messages, social media posts, images, and videos [29].
Eligibility criteria
Potential participants must first agree to an online
informed consent before beginning the baseline
online survey. Inclusion criteria are being born
biologically male, age 16 years or older,
self-reported previous anal sex with another man,
and current residence in China. Men who report
past HBV vaccination, HBV testing, or HCV testing
will be excluded. Those who report uncertain past
HBV vaccination, HBV testing, or HCV testing will
be considered eligible. All eligible participants must
provide a working unique mobile phone number
and WeChat account to be enrolled.
Fig. 1 Trial design to evaluate a crowdsourced intervention to increase hepatitis testing among MSM in China
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Randomization and allocation
Once enrolled, participants will be assigned in a 1:1 ratio
to intervention or control through a randomization pro-
cedure using permuted blocks. SAS software (Cary,
North Carolina, USA) will be used to create the alloca-
tion sequence using the PROC PLAN and RANUNI
functions. The allocation sequence will be applied to
participants sequentially in the order in which they were
enrolled. This RCT is not blinded. Participants will be
able to determine their assignment based on whether
they received intervention materials during the study
period. The primary investigator (TF) will be aware of
randomization assignment because intervention mate-
rials will be delivered through WeChat.
Intervention and control
Men randomly assigned to the intervention arm will
receive a two-part crowdsourced intervention. The
multimedia component of the intervention will deliver
two images and two one-minute videos to men through
WeChat. One image or video will be delivered every
other day after enrolment, for a total of 8 days. Interven-
tion images and videos were developed through a public
nationwide crowdsourcing contest conducted in China
in 2017.
A steering committee consisting of representatives
from 13 national and international organizations was
formed to organize a contest to solicit multimedia mate-
rials that promote HBV and HCV testing and reduce
stigma toward people living with viral hepatitis. An
initial public call for images and one-minute videos was
promoted through social media and partner organiza-
tions. In total, 168 submissions were collected between
February and May 2017. All submissions were first eval-
uated for eligibility and were then reviewed by a judging
panel composed of steering committee members. Judges
evaluated submissions on a 10-point scale based on each
submission’s innovation and creativity, capacity to pro-
mote hepatitis testing, and potential to increase social
media responsiveness. The twelve highest scoring entries
were selected as semi-finalists and provided with feed-
back for improvement. Semi-finalists then had the
opportunity to resubmit their images or videos. Eight
submissions (four images and four videos) were selected
as contest finalists, with five receiving third place, two
receiving second place, and one receiving first place.
To select the finalist entries most appropriate for
MSM in China, an online poll was conducted in August
2017. The poll was promoted through local MSM orga-
nizations and their social media accounts. Thirty MSM
were asked to rank the four finalist videos, and a separ-
ate 30 MSM were asked to rank the four finalist images.
The two top-ranked images and videos from this poll
were selected as materials to be used in the intervention
arm of the RCT (intervention images are available in
Supplementary Materials as Additional file 1 and
Additional file 2).
Because the strength of crowdsourcing includes not
only the inflow of creative solutions and new ideas, but
also facilitation of active participation and community
engagement, the intervention will also include a partici-
patory component. After viewing each image and video,
men will be invited to participate in a crowdsourcing
contest. Men can submit 50- to 200-word suggestions
for how to improve the intervention images and videos
to convince more MSM in China to receive hepatitis
testing. A contest steering committee composed of
hepatitis experts and community representatives will
judge each submission on a 10-point scale, and the
highest-scoring eight submissions will receive prizes.
Men randomly assigned to control will not view any
images or videos and will not be invited to submit ideas
for improving hepatitis testing promotional materials.
All participants will be informed at enrolment that costs
of HBV and HCV testing during the four-week study
period can be reimbursed. Because this study is designed
as a pragmatic trial with results that will be generalizable
to multiple settings, men will be allowed to receive
hepatitis testing at any hospital, clinic, or healthcare
centre of their choosing.
Outcomes
HBsAg and anti-HCV IgG test uptake confirmed by test
report photo at 4 weeks post-enrolment is the primary
outcome of this study. This dichotomous outcome has
two component endpoints (HBsAg test uptake and
anti-HCV IgG test uptake) that constitute a single com-
posite endpoint. Selection of HBsAg and anti-HCV IgG
as serological assays is based on WHO testing guidelines
[13]. A participant will only be counted as having the
primary outcome if he has submitted a photo to
researchers through WeChat or the online follow-up
survey that clearly displays tester age, tester sex, test
date, and HBsAg and anti-HCV IgG results. If submitted
HBV test report photos also include anti-HBs and
anti-HBc serological assays, these results will be
recorded. Test date must fall within the four-week
period (28 days) after enrolment for test uptake to
be confirmed.
Confirmed HBsAg and anti-HCV IgG test uptake as
independent component endpoints are secondary
outcomes. Secondary outcomes also include the follow-
ing self-reported items on the follow-up survey: HBsAg
test uptake, anti-HCV IgG test uptake, HIV test uptake,
chlamydia test uptake, gonorrhoea test uptake, syphilis
test uptake, visit with specialist physician after HBV or
HCV testing, and change in stigma toward people living
with HBV during the four-week study period.
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Self-reported HBV vaccination uptake among all partici-
pants and those with confirmed susceptibility to HBV
infection (negative anti-HBs and negative HBsAg by test
report photo) are also secondary outcomes. Definitions
for all study outcomes are provided in Table 1.
Sample size
A pilot study was conducted in November 2017 to
inform sample size calculations. Pilot results are detailed
in Supplementary Materials (see Additional file 3).
Assuming a confirmed HBV and HCV testing response
of 8.5% among intervention participants, 3.0% among
control participants, a two-sided significance level of 5%,
and 10% not evaluable (e.g., missing data), a total sample
size of 674 men would be needed to have 80% power for
an exact test. Power was calculated in SAS version 14.2
using the twosamplefreq statement in PROC POWER.
The total sample size was rounded up to 700 for con-
venience, which corresponds to approximately 82%
power under the above assumptions.
Data collection and measures
Baseline and follow-up surveys will be delivered to
mobile devices and completed online using Wenjuanx-
ing (Sojump, Shanghai, China), a web-based survey tool
that meets industry standards for security and function-
ality. Both surveys were written in Chinese, and 12 local
MSM were asked to provide feedback to ensure
questions are clear and culturally appropriate.
The baseline survey will first ask respondents to
answer questions regarding eligibility criteria. If
eligible, respondents will be asked to complete the
remainder of the survey. The baseline survey will
include the following domains: sociodemographic
characteristics, sexual risk factors for viral hepatitis in-
fection, previous HIV/STI testing behaviours and diag-
noses, stigma toward people living with HBV,
engagement in health promotion activities in the
MSM community, access to primary healthcare ser-
vices, access to MSM-competent healthcare, experi-
ences with MSM stigma in healthcare settings, and
trust in healthcare providers. Twenty-eight questions
will measure sexual risk factors for viral hepatitis
infection, which were adapted from the validated
HCV-MOSAIC risk score for HCV infection among
MSM [30]. Stigma toward people living with HBV will
be assessed using the Toronto Chinese HBV Stigma
Scale, a 20-item index validated for Chinese-speaking
populations [12]. Engagement in health promotion ac-
tivities will be measured through six items used in
previous evaluations of crowdsourced interventions
[31]. Access to MSM-competent healthcare will be
assessed through three questions adapted from a re-
cent survey investigating MSM-competent physicians
in China [32]. Seven questions adapted from research in
the United States will be used to measure experiences
with MSM stigma in healthcare settings and trust in
healthcare providers [33, 34].
Participants will receive a WeChat message 3 weeks
after enrolment asking them to complete a follow-up
survey within 1 week. The follow-up survey will collect
information regarding the following self-reported out-
comes: HBsAg and anti-HCV IgG test uptake, consult-
ation with a specialist physician regarding HBV and
HCV test results, HBV vaccination uptake, and HIV and
STI test uptake since enrolment. Stigma toward people
living with HBV will be reassessed. Participants will be
asked to report their exposure to intervention materials
and behaviours sharing intervention materials on social
media during the four-week study period. Men in the
intervention and control arms will receive the same
follow-up survey. Men who have not completed the
follow-up survey 2 days prior to the end of the
four-week study period will be sent a reminder message.
Both the baseline and follow-up surveys are expected to
take less than 10 min to complete and are available in
Supplementary Materials (see Additional file 4 and
Additional file 5).
At any time after enrolment and throughout the
four-week study period participants can submit photos
of their HBV and HCV test reports through WeChat.
Test report photos can also be uploaded along with the
follow-up survey. The following information will be
extracted and recorded from submitted photos: tester
age, tester sex, date of test, and test result. No other
personally identifiable information will be extracted.
Mobile phone numbers and WeChat accounts will be
used to link information extracted from test report
photos to baseline and follow-up survey responses.
Among men assigned to the intervention arm, sugges-
tions for improving crowdsourced images and videos will
be collected through a web-based survey form hosted on
Wenjuanxing. Information on contest participation will
be linked to baseline and follow-up survey responses
using mobile phone numbers and WeChat accounts.
Confidentiality
Survey data will be collected through and stored on a
secure online survey platform (Wenjuanxing). Photos of
test reports will be collected through a secure online
messaging platform (WeChat) or a secure online survey
platform (Wenjuanxing). Participants will be instructed
to cover or obscure their name and other personal iden-
tifying information on the test report to protect their
privacy. Data will be transmitted using 128-bit encryp-
tion across the internet and mobile data networks.
Responses to both baseline and follow-up surveys, in-
cluding participant mobile phone numbers and WeChat
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account numbers, will be stored on a secure server
which can be accessed with login information known
only to the research team.
Incentives and reimbursement
Participants who complete the initial survey will receive
4.73 USD (30 RMB), and those who complete the
follow-up survey will receive an additional 7.89 USD (50
RMB). All testing costs up to 11.04 USD (70 RMB) for
HBV and 6.31 USD (40 RMB) for HCV will be reim-
bursed to men who submit photos of their test results.
Reimbursement amounts are based on prices of national
standard HBV testing items (qualitative HBsAg,
Anti-HBs, and Anti-HBc serological assay) and HCV
testing items (qualitative anti-HCV IgG serological
assay), respectively.
Men in the intervention arm who submit suggestions
for improving hepatitis testing promotion materials will
be eligible to receive contest prizes. Prizes of 78.88 USD
(500 RMB), 31.55 USD (200 RMB), and 15.77 USD (100
RMB) will be distributed to one first-place finalist, two
second-place finalists, and five third-place finalists,
respectively. All incentives and reimbursements will be
distributed as electronic money transfers through
WeChat.
Monitoring
A data monitoring committee will not be formed for this
RCT because potential for harm to participants is
minimal. If any person feels they have experienced an
adverse event or unwanted effect from participating in
this RCT, they can withdraw at any time. A telephone
number and WeChat account will be provided to
participants to contact the primary investigator with
questions or concerns.
Data analysis
Primary analysis
Participant baseline characteristics and outcomes will be
summarized using descriptive statistics. The primary
analysis will evaluate the hypothesis that the crowd-
sourced intervention is superior to control (i.e. no
exposure) in increasing HBV and HCV testing among
MSM in China. The proportion of men with confirmed
HBsAg and anti-HCV IgG test uptake will be calculated
for the intervention and control arms separately using a
two-sided binomial 95% CI. The difference in propor-
tions with test uptake will be calculated (intervention –
control) with a corresponding Wald 95% CI. A Z-test
will also be performed to compare the difference in pro-
portions with test uptake between the intervention and
control arms. If the 95% CI for the difference in prob-
abilities is entirely above zero, then the intervention will
be declared superior to control. If testing proportions
are lower than anticipated such that statistical assump-
tions of the Wald CI are not met, then an exact 95% CI
for the difference in probabilities will be used.
The effect of the intervention on HBV and HCV test-
ing will first be evaluated using an intention to treat ana-
lysis that includes men lost to follow-up. Those who are
lost to follow-up or do not respond will be counted as
having not tested for HBV and HCV. An as-exposed
analysis will also be performed that reassigns partici-
pants based on their self-reported exposure to the inter-
vention materials and adjusts for potential confounders
measured in the baseline survey.
Effect measure modification analysis
Effect measure modification analyses will evaluate
whether the effect of the intervention on confirmed
HBV and HCV testing varied in relation to the following
factors measured at baseline: (1) engagement in health
promotion activities in the MSM community, (2) ac-
cess to primary healthcare services, (3) access to
MSM-competent healthcare, (4) experiences with
MSM stigma in healthcare settings, (5) trust in
healthcare providers, and (6) age cohort (16–24 years
old, 25–29 years old, and ≥ 30 years old). Age cohorts
were selected based on previous epidemiological stud-
ies investigating HBV infection and vaccine-associated
immunity among MSM in China [12].
Missing data plan
Any participants lost to follow-up will be included and
assumed to have not achieved the primary and second-
ary outcomes during the study period. If an outcome is
missing for < 15% of participants, analyses will use a
complete-case approach. If an outcome is missing for
≥15% of participants, analyses will use multiple
imputation.
Secondary analyses
The intervention and control arms will also be com-
pared for differences in proportions of men achieving
secondary outcomes, including confirmed HBsAg test
uptake (independent of anti-HCV IgG test uptake),
confirmed anti-HCV IgG test uptake (independent of
HBsAg test uptake), self-reported HBsAg and anti-HCV
IgG test uptake, HBV vaccination, and HIV and STI test
uptake during the four-week study period. The analysis
approach will be as described for the primary outcome.
Change in stigma toward people living with HBV from
baseline to week four will be calculated and compared
between the intervention and control arms using a
Wilcoxon ranksum test.
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Discussion
This study is unique in terms of setting, population,
intervention type, and outcome ascertainment, and will
therefore make important contributions to the existing
literature. A recent systematic review found that few
controlled trials have previously evaluated interventions
to increase HBV and HCV test uptake [26]. Only one in-
cluded study had been conducted in a middle-income
country, and none had investigated hepatitis testing
among MSM [26]. This RCT will extend our under-
standing of hepatitis testing interventions by investigat-
ing MSM in China, a middle-income country with a
high burden of hepatitis.
While crowdsourcing has been used to increase HIV
testing and condom use, [23, 24] this innovative type of
intervention has not been previously applied to HBV
and HCV test promotion. By disseminating test promo-
tion materials through social media and encouraging
participants to generate content, this crowdsourced
intervention has the potential to reach previously
underserved MSM and improve hepatitis testing among
a population with poor test uptake. Additionally, social
media platforms are frequently used by MSM inside and
outside China to share content, including health promo-
tion materials [35]. The results of this trial will therefore
have implications for future hepatitis testing campaigns
targeting MSM in settings with wide-spread social
media utilization.
Finally, past studies of hepatitis testing behaviours
among MSM have relied on self-report to ascertain
whether men had previously received testing [36–38].
However, the reliability of self-reported HBV and HCV
test uptake is unknown and potentially subject to
recall, ascertainment, and social acceptability biases.
This RCT will confirm HBV and HCV test uptake through
electronic submission of test report photos. This novel
method of outcome ascertainment will provide re-
searchers with reliable biomarker data by verifying testing
uptake through hospital or clinic documentation. Partici-
pants will be able to receive testing at any facility of their
choosing. Because test uptake will not be limited to a spe-
cific region or clinical context, the generalizability of re-
sults will be enhanced, and this study will be able to
inform the design of future hepatitis testing services across
a wide-variety of settings.
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